File(s) under permanent embargo
A patient with neuro-Behçet's disease is successfully treated with etanercept: Further evidence for the value of TNFα blockade
journal contribution
posted on 2023-05-22, 04:05 authored by Jane AltyJane Alty, Monaghan, TM, Bamford, JMBehcet's disease is a chronic relapsing multisystem vasculitis with 49% of cases involving the CNS. Recently there have been two reports of neuro-Behcet's disease (NB) successfully treated with the tumour necrosis factor α (TNFα) monoclonal antibody infliximab. We describe a patient with longstanding NB who was poorly responsive to azathioprine, cyclosporin, thalidomide and methotrexate. She showed a remarkable response when treated with the recombinant human TNFα receptor protein, etanercept. To the best of our knowledge this is the first report of NB successfully treated with etanercept.
History
Publication title
Clinical Neurology and NeurosurgeryVolume
109Pagination
279-281ISSN
0303-8467Department/School
Wicking Dementia Research Education CentrePublisher
Elsevier Science BvPlace of publication
Po Box 211, Amsterdam, Netherlands, 1000 AeRepository Status
- Restricted